Flu News and Research

RSS

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Americans looking to impact their cold and flu symptoms this season may have a new weapon at their disposal. A randomized, double-blind, placebo-controlled study just published by the University of Florida determined that Kyolic Aged Garlic Extract (AGE) may reduce the duration of symptoms associated with common colds or flus by as much as 61 percent.

16 Mar 2012

Allergy-free egg in the making

Researchers at CSIRO and experts at Geelong's Deakin University have found a way to “switch off” four egg allergens. These modified eggs could produce chickens that lay hypoallergenic eggs but the genes and DNA of the chicken would remain unaltered.

15 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

AMGA presents Medical Group Preeminence Award to VMMC

The American Medical Group Association today presented the Medical Group Preeminence Award to Virginia Mason Medical Center (VMMC), a health system based in Seattle, WA. The presentation took place at the AMGA 2012 Annual Conference, being held March 8-10 at the Manchester Grand Hyatt.

12 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0M

GenMark Diagnostics, Inc. today reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2011. The Company will release its full financial statements and related disclosures along with its Form 10-K filing for the period ending December 31, 2011 upon completion of its independent audit, which includes the Company's first Sarbanes-Oxley audit of internal controls, by March 15, 2012.

9 Mar 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Rep. Sensenbrenner sends 'fact-finding letter' to White House science adviser about bird flu studies

"Representative Jim Sensenbrenner (R-Wis.), a former head of the House committees on science and the judiciary, and currently vice chair of the House Committee on Science, Space, and Technology, last week sent a 'fact-finding letter' to White House science adviser John Holdren, asking pointed questions about how the U.S. government has handled the controversy" surrounding two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, "and questioning whether it should have funded the two flu studies," ScienceInsider reports.

6 Mar 2012

Microneedle vaccine patches may effectively protect against flu

Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses by the Emory and Georgia Tech research team helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

6 Mar 2012

Mount Sinai researchers argue different views of how to safely handle H5N1 flu viruses

In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.

6 Mar 2012

Survey: Americans spend more for health care than people in other countries

The report from the International Federation of Health Plans found that Americans pay more for physician time, for scans, surgery and drugs than people in other countries. Also in the news, other reports from the health care marketplace explore the lack of insurance coverage for reproductive-age women and the growth in the number of companies that are offering incentives to their employees to better manage their health.

5 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

New tool to map extent of traumatic brain injury

Traumatic brain injury among soldiers, sportsmen and women and accident survivors are common but may go undetected at the time of the event and manifest later in life. Now scientists are testing a tool that lights up the breaks these injuries leave deep in the brain's wiring, much like X-rays show broken bones.

4 Mar 2012

EC grants marketing authorization for Baxter's VEPACEL to treat influenza A

Baxter International Inc. announced today that the European Commission (EC) has granted marketing authorization for VEPACEL in all European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway.

From Baxter International Inc. 2 Mar 2012

Quadrivalent flu vaccine that fights against four strains of Influenza approved

The FluMist Quadrivalent vaccine from AstraZeneca's MedImmune unit protects against two strains of influenza A and two strains of influenza B, and is approved for people ages 2 to 49. Similar to the previously approved FluMist, the new vaccine is a nasal spray that delivers weakened strains of the virus. The vaccine, FluMist Quadrivalent (MedImmune), will be available for the 2013-2014 flu season.

2 Mar 2012

U.S. panel may re-evaluate bird flu research after scientists present new data about risks to humans

Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.

1 Mar 2012

Parkinson's drug Amantadine may help brain injury victims: Study

The study shows that Amantadine helps boost brain levels of dopamine, a neurotransmitter linked to arousal. And for patients who are in a vegetative state following a brain injury, the drug can help -- possibly by improving responsiveness during rehabilitation.

1 Mar 2012

NKT cells may reduce monocytes accumulation, prevent lung injury in severe flu

While some scientists report engineering a super virulent strain of the H5N1 influenza virus, which could potentially wipe out a significant percentage of the human population, another group of researchers from the United Kingdom now reports a discovery that may one day help mitigate the deadly effects of all flu strains.

1 Mar 2012

FDA approves MedImmune's FluMist Quadrivalent vaccine

MedImmune today announced that the U.S. Food and Drug Administration (FDA) has approved FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of influenza.

29 Feb 2012

Biogen Idec announces new easier to use injection for multiple sclerosis

The Food and Drug Administration approved the company's Avonex pen, an injection designed to reduce pain and anxiety when patients self-administer the drug. The FDA also approved a new dosing schedule for the drug intended to reduce flu-like symptoms often associated with the drug.

29 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012